Every letter we have printed

The clinical trials that inform this discussion ran for a fixed period and stopped. Every statement about maintenance beyond that horizon is extrapolation, and the confidence with which extrapolations are stated in general discussion is not warranted by their source.

A note on the chain between synthesis and certificate. The document that matters is the one that names who took the sample and when. A report on a sample the seller chose, packed and posted describes that sample honestly and describes the lot only by assumption, and the assumption is the part nobody writes down.

A sample that arrives at a laboratory in an unlabelled tube tells the analyst nothing about where it came from, and the report can only ever describe what was in the tube. The certificate says the material is pure; it cannot say the material is yours.

On the difference between a release specification and a shelf-life specification: outside a regulated setting almost nobody distinguishes them, and it matters. A limit that a lot met on the day it was made is not a promise about the lot in the drawer eighteen months later, and the certificate is a photograph rather than a warranty.

Appearance is the most under-rated line on the page. It is a genuine observation, it is free, and a cake described as white when the vial in front of you is faintly yellow tells you something has happened between the two. Everything else on the certificate requires an instrument to argue with.

Drawing through a stopper blunts a needle immediately, which is the argument for changing it before anything else happens. It is a practice recommendation with a physical basis rather than a ritual.

Gauge numbering runs backwards and it catches people out constantly. A higher number is a thinner needle. A reader who assumes the number tracks the diameter will order the opposite of what they wanted, and the packaging does nothing to help.

A quibble on your dead-space figure. You give two to seven microlitres for insulin-type needles, which is right for fixed-needle syringes, but the detachable pen needle plus syringe hub combinations sold in this market are considerably worse and you should say so.

The stopper wipe is the step with the best evidence behind it and the one most often skipped, presumably because the vial looks clean. Contact time matters as much as the wipe: alcohol needs to dry to have done anything.

What the single figure hides is the shape of what is left over. Ninety-eight per cent with one impurity at two is a different material from ninety-eight per cent with forty impurities at one twentieth each, and a buyer who cares about the second case is given no way to tell them apart.

Our institution requires two decimal places on a purchase specification and I have never once seen a certificate that could support the second one. The precision of the printed number and the precision of the measurement behind it have drifted apart, and nobody in the chain has an incentive to say so.

The reporting asymmetry is worth naming. Severe events are newsworthy and mild ones are not, so the visible discussion is drawn from the tail of a distribution and read as though it described the middle.

Distinguishing expected effects from something that needs attention is the most valuable service a piece like this can perform, and the useful discriminators are pattern and trajectory rather than severity at a moment. Anything that is worsening rather than settling is a different conversation.

Self-reported incidence collected in online communities is not comparable with trial incidence in any direction, and it is put side by side with it regularly. Different populations, different definitions, different collection, one chart.

Bacteriostatic diluent contains a preservative and is intended for multiple withdrawals; sterile water is not. That distinction is the one thing in this whole subject that a supplier could usefully print on the box, and I have never seen it printed. Research-use material is not approved for human use in any event, and the storage physics is the same either way.

In-use figures quoted in this market trace back, when you follow them, to manufacturer statements about a different formulation of a different product. The chain of citation is worth publishing on its own.

A temperature indicator that has not tripped tells you the parcel did not exceed a threshold for a duration. It does not tell you the parcel stayed cold, and the two readings are routinely confused by everybody including me until recently.

On amber glass: it is not merely cheap, it is standard in the wider chemical supply trade for anything with a chromophore. The fact that this market ships peptides in clear glass is a sign of who is doing the filling more than of any decision about photostability.

Storage of a reconstituted vial is where practice and evidence diverge most. The chemistry of the solution and the microbiology of a repeatedly entered container are two separate clocks, and only one of them is discussed. Material for research use is not approved for human use, and the storage question is the same regardless.

Hand hygiene before anything else is the single highest-yield step in every published account of technique in any setting, and it is the step most often skipped because it is the least visible.

In defence of the retention-time comparison your article is rude about: run against a properly characterised standard on a stated method, co-elution plus a matching mass is genuinely strong evidence. The weakness is not the logic, it is that the standard is usually a previous lot of the same product.

Tandem mass spectrometry with sequence coverage stated as a percentage is the thing to ask for, and the percentage is the part that gets omitted. Sixty per cent coverage on a thirty-residue peptide leaves twelve residues unverified, and where those twelve sit determines whether the result means anything.

For readers who want a rule of thumb: if the report does not state a resolving power, assume it was sufficient to see the molecule and insufficient to see anything close to it. That assumption has been right every time I have been able to check it.

On your point about D-amino acids: chiral amino-acid analysis after hydrolysis is not exotic and several contract laboratories offer it. The obstacle is that hydrolysis itself racemises a few per cent of most residues, so the method has a blank problem, and interpreting a low-level D content is genuinely difficult rather than merely expensive.

The version I would accept is a mark that renders the determination date, the molecule and the report number in the image, links to the report and greys itself after twelve months. Everything in that list is trivial to build and none of it exists.

A note on the buyers who do click through. Of the ones I have spoken to, most read the purity figure and stop. The method, the date and the sample identity are all on the page and are not being read, which suggests the reform needed is in what is emphasised rather than in what is disclosed.

I would like the laboratory’s receipt condition printed on the report. Arrived cold, arrived warm, arrived with the seal broken — three observations, made anyway on arrival, and discarded before the document is written.

What a badge cannot do is carry forward in time. A report on a lot filled eighteen months ago says nothing about the lot shipping today, and the badge sits in the page template rather than on the product. Verification has a date and the design of these things hides it.

A short note of thanks. I sent this article to two people who needed it and neither has argued with me since.

The protein intake figures in general circulation come largely from resistance-training studies in energy balance, and applying them to a substantial energy deficit is an extrapolation in the direction of needing more rather than less. Your article says this and most coverage does not.

Grams per kilogram of what is the question nobody asks. Total mass, lean mass and a reference mass give substantially different targets for the same person, and the literature uses all three without always saying which.

Receptor occupancy arguments are used loosely in this discussion. Occupancy and effect are related by a function that is rarely linear, and quoting a saturation figure as though it settled the question is not supported by the pharmacology.

In this market the nominal dose is derived from an assumed concentration, so the real ceiling question is a question about content. A figure calculated from a label is not a dose in the sense the trial literature uses the word.

The trial schedules escalated on a fixed calendar regardless of response, which is a design choice for comparability rather than a recommendation. Reading them as optimal is reading a protocol as advice.

The gap between the printed schedule and the practised one is real and your piece is right to describe it without approving of it. The label schedule was the one studied; every departure from it is an extrapolation, and the people making those departures are rarely the people who would be asked to defend them.

Aspartate isomerisation changes nothing about the mass at all. Nor does racemisation of a single residue. Both alter the molecule in ways that a chromatographic method developed for the purpose can sometimes resolve, and that a mass measurement cannot see under any circumstances.

Aggregates are invisible in the sense that matters: they are still the right molecule, so identity confirms, and they may be excluded from a reversed-phase separation entirely by never coming off the column. Whatever stays on the stationary phase is not in the denominator.

Resolving power and mass accuracy are independent and your article treats them as one virtue. A time-of-flight instrument can be well calibrated and modest in resolving power; an ion trap can resolve and drift. The two specifications answer separate questions and a report should carry both.

A mass spectrum reproduced at postage-stamp size in the corner of a certificate is decoration rather than evidence. If the document is going to carry the spectrum, it should carry it at a size where the isotope pattern is readable, or it should carry the data file reference instead.

Supply interruption is the underdiscussed maintenance risk. A plan that depends on continuous availability of a specific product is a plan with an external dependency, and the last two years have shown how that dependency behaves under stress.